ELIAS News2020-05-03T19:08:59-06:00

News & Updates

ELIAS Animal Health Appoints Dr. Brian Andresen as Sales and Marketing Leader

Olathe, Kan., June 8, 2020 – ELIAS Animal Health, a clinical stage development company advancing novel treatments for cancer in companion animals, announces the appointment of Brian Andresen, DVM as Vice President of Sales & Marketing. Dr. Andresen brings an extensive sales and marketing background to the company, including the development, commercialization, launch, and leadership of animal health, human pharmaceutical, and biopharmaceutical brands. “With experience in both veterinary science and sales and marketing, Brian brings a unique and well-rounded perspective of the animal health products market,” said ELIAS CEO, Tammie Wahaus. “I am thrilled to add Brian to this team [...]

June 8th, 2020|

ELIAS Animal Health announces clinical trial launch: ECI-OSA-04 for the treatment of canine osteosarcoma

Olathe, Kan., May 28, 2020 – ELIAS Animal Health, a clinical stage development company advancing novel treatments for cancer in companion animals, today announced the initiation of a follow-up study to pursue licensure of the ELIAS cancer immunotherapy (ECI®) treatment combined with surgery as an alternative to chemotherapy for dogs diagnosed with osteosarcoma, a deadly form of bone cancer. In a preliminary clinical study, the median survival time was 415 days, compared to 270-300 days for traditional chemotherapy treatments, suggesting that ECI holds the potential to significantly improve survival times and quality of life for the canine patient. This clinical trial [...]

May 28th, 2020|

ELIAS Animal Health Clinical Dataset Supports FDA Fast Track Designation for TVAX Biomedical

Exciting progress in the fight against cancer for both pets and humans On April 27, the US Food and Drug Administration (FDA) approved the application by our development partner, TVAX Biomedical, for Fast Track Designation for treatment of glioblastoma multiforme (GBM) with the immunotherapy technology ELIAS Animal Health is also using for treatment of osteosarcoma in dogs. Founded on the principle of translational medicine, ELIAS is especially pleased to have supported this major achievement. The efficacy and safety data from the previously completed canine osteosarcoma study conducted by ELIAS was an important component of the TVAX Fast Track application and [...]

May 5th, 2020|
Go to Top